Atlas Antibodies
Atlas Antibodies AB is a biotechnology company that specializes in the development and production of advanced antibodies and reagents for biomedical research, particularly in mass spectrometry-based quantitative proteomics. Founded in 2006 by researchers from the Royal Institute of Technology and Uppsala University, the company originated from the Human Protein Atlas project. Based in Bromma, Sweden, Atlas Antibodies provides a wide range of research reagents targeting various human proteins, including primary antibodies, blocking antigens, and antibody panels for specific applications in neuroscience, organelle studies, and cancer research. The company's products are designed to facilitate both basic and clinical research, thereby supporting advancements in understanding and treating diseases such as cancer and neurological disorders. Atlas Antibodies markets and sells its products globally through online platforms.
Top Stages
2 past transactions
Evitria
Acquisition in 2021
Evitria AG is a biotechnology company based in Schlieren, Switzerland, specializing in the research and development of protein design and expression products. Founded in 2010, Evitria primarily focuses on CHO-based transient expression of antibodies, including bispecific and fusion antibodies. The company has developed a robust protein expression platform that allows for the rapid production of significant quantities of protein in HEK293 and CHO cells, facilitating adeno-associated virus and lentivirus-mediated gene transfer. With a proven track record of over 30,000 transfections and 5,000 antibodies expressed and purified for a diverse clientele ranging from academic laboratories to global biopharmaceutical companies, Evitria offers a comprehensive suite of services, including custom monoclonal antibodies and gene expression services, to meet the needs of its clients efficiently and effectively.
HistoCyte Laboratories
Acquisition in 2021
HistoCyte Laboratories specializes in the development of cell line materials that provide control for immunohistochemical assays used in cancer diagnosis. Established in 2014, the company has built a notable presence in key markets, including the UK and USA, and is poised for accelerated growth as the demand for cell line controls rises. HistoCyte Laboratories utilizes innovative technology to create tissue-like controls from cell lines, ensuring reproducibility and an inexhaustible supply. These high-density cell preparations maintain their original morphology and are designed for same-slide use in immunohistochemistry and in situ hybridization. The company's objective is to offer cost-effective control materials that enhance the reliability of laboratory results, thereby improving the overall quality of diagnostic services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.